New drug combo trial targets genetic flaws in blood cancers
NCT ID NCT04493138
Summary
This study is testing a combination of two drugs, azacitidine and quizartinib, for adults with specific types of bone marrow and blood cancers (MDS and MDS/MPN). The goal is to find the safest and most effective dose and to see how well the combination controls the disease in patients whose cancers have particular genetic changes (FLT3 or CBL mutations). This is an early-phase trial focused on safety and initial effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.